Literature DB >> 14634238

Development of drug-resistant models.

Helen M Coley1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14634238     DOI： 10.1385/1-59259-406-9:267

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


× No keyword cloud information.
  13 in total

1.  Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Carlos M Telleria
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

2.  The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.

Authors:  Marzieh Armat; Taiebeh Oghabi Bakhshaiesh; Mehdi Sabzichi; Dariush Shanehbandi; Simin Sharifi; Ommoleila Molavi; Jamal Mohammadian; Mohammad Saeid Hejazi; Nasser Samadi
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

3.  Repopulation of ovarian cancer cells after chemotherapy.

Authors:  Carlos M Telleria
Journal:  Cancer Growth Metastasis       Date:  2013-02-18

4.  Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.

Authors:  Eun-Hye Hur; Seung-Hyun Jung; Bon-Kwan Goo; Juhyun Moon; Yunsuk Choi; Dae Ro Choi; Yeun-Jun Chung; Je-Hwan Lee
Journal:  Oncotarget       Date:  2017-02-14

5.  Establishment and molecular characterization of decitabine-resistant K562 cells.

Authors:  Xiang-Mei Wen; Ting-Juan Zhang; Ji-Chun Ma; Jing-Dong Zhou; Zi-Jun Xu; Xiao-Wen Zhu; Qian Yuan; Run-Bi Ji; Qin Chen; Zhao-Qun Deng; Jiang Lin; Jun Qian
Journal:  J Cell Mol Med       Date:  2019-02-22       Impact factor: 5.310

6.  Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties.

Authors:  Bhanvi Mishra; Sufang Zhang; Hong Zhao; Zbigniew Darzynkiewicz; Ernest Y C Lee; Marietta Y W T Lee; Zhongtao Zhang
Journal:  Cancer Biol Ther       Date:  2018-11-14       Impact factor: 4.742

7.  Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells.

Authors:  Z S Siti; A M I Seoparjoo; H Shahrul
Journal:  Heliyon       Date:  2019-04-28

8.  Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Authors:  Jason T Fong; Ryan J Jacobs; David N Moravec; Srijayaprakash B Uppada; Gregory M Botting; Marie Nlend; Neelu Puri
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

9.  Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

Authors:  Deven Etnyre; Amanda L Stone; Jason T Fong; Ryan J Jacobs; Srijayaprakash B Uppada; Gregory M Botting; Supriya Rajanna; David N Moravec; Manohar R Shambannagari; Zachary Crees; Jennifer Girard; Ceyda Bertram; Neelu Puri
Journal:  Cancer Biol Ther       Date:  2014-06-11       Impact factor: 4.742

10.  Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.

Authors:  Hamid Ali Nagi Al-Jamal; Siti Asmaa Mat Jusoh; Rosline Hassan; Muhammad Farid Johan
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.